Pain & Inflammation
Cross-class anti-inflammatory and analgesic mechanisms (BPC-157, TB-500, LL-37, ARA-290).
Overview
Pain and inflammation peptide research investigates agents that reduce nociceptive signaling, resolve inflammation without indiscriminate immunosuppression, and support nerve regeneration in chronic-pain syndromes. ARA-290 (cibinetide) is the most clinically advanced: a non-erythropoietic erythropoietin derivative engineered to bind the innate-repair receptor (IRR, a beta-common/EPOR heterocomplex) without raising hematocrit. BPC-157 and TB-500 contribute analgesic effects in injury models via tissue-repair acceleration rather than direct nociception modulation. KPV exerts anti-inflammatory effects through the melanocortin pathway. LL-37 modulates inflammation at mucosal interfaces. Together, the category emphasizes upstream inflammation resolution over symptomatic analgesia.
Biological Pathways
Ara-290
Popular Name: Cibinetide, ARA290, ARA-290 peptide
$XX.XX
BPC-157
Popular Name: Body Protection Compound 157, BPC157, BPC 157
$XX.XX
KLOW
Popular Name: KLOW stack, TB10 BPC10 GHK50 KPV10, KLOW blend
$XX.XX
KPV
Popular Name: Lys-Pro-Val, Alpha-MSH tripeptide core, MSH fragment
$XX.XX
LL-37
Popular Name: Cathelicidin, hCAP-18 fragment, CAP-18
$XX.XX
TB-500 / Thymosin Beta-4
Popular Name: TB500, TB-500, Thymosin Beta-4
$XX.XX